46.05
-0.80
(-1.71%)
After Hours: 46.30
+0.25
(0.54%)
Jun 19, 7:41PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 46.03 - 47.03 |
| 52 week | 30.64 - 49.57 |
| Open | 46.60 |
| Vol / Avg. | 0.00/12.91M |
| Mkt cap | 75.64B |
| P/E | 52.55 |
| Div/yield | 0.35/3.04 |
| EPS | 0.88 |
| Shares | 1.64B |
| Beta | 0.46 |
| Inst. own | 69% |
Events
Jul 22, 2013
Q2 2013 Bristol-Myers Squibb Earnings Release
Jun 11, 2013
Bristol-Myers Squibb at Goldman Sachs Healthcare Conference -
Jun 2, 2013
Bristol-Myers Squibb Investor Event: ASCO 2013 -
May 21, 2013
Bristol-Myers Squibb at UBS Global Healthcare Conference
May 15, 2013
Bristol-Myers Squibb at Bank of America Merrill Lynch Health Care Conference -
May 7, 2013
Bristol-Myers Squibb 2013 Annual Meeting of Stockholders -
Apr 25, 2013
Q1 2013 Bristol-Myers Squibb Earnings Conference Call -
Apr 25, 2013
Q1 2013 Bristol-Myers Squibb Earnings Release
Apr 8, 2013
Bristol-Myers Squibb CSO Succession -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 16.26% | 14.19% |
| Operating margin | 17.59% | 13.28% |
| EBITD margin | - | 31.85% |
| Return on average assets | 6.96% | 7.26% |
| Return on average equity | 17.91% | 13.25% |
| Employees | 28,000 | - |
| Carbon Disclosure Rating | - | 89/100 |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
About Company - Wikipedia
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States (U.S.), Puerto Rico and in 6 foreign countries. In February 2012, it acquired Inhibitex, Inc. (Inhibitex). In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. In August 2012, Synergy Pharmaceuticals Inc announced that it signed an Asset Purchase Agreement with the Company and acquired the assets related to FV-100, an orally available nucleoside analogue, being developed for the treatment of shingles.
Officers and directors
| Lamberto Andreotti | Chief Executive Officer, Director | |
| Charles A. Bancroft | Chief Financial Officer, Executive Vice President | |
| Giovanni Caforio M.D. | President, U.S. Pharmaceuticals | |
| Louis S. Schmukler | President - Global Manufacturing and Supply | |
| Elliott Sigal M.D., Ph.D. | Executive Vice President, Chief Scientific Officer, President - Research and Development, Director | |
| Beatrice J. Cazala | Executive Vice President - Commercial Operations | |
| Paul von Autenried | Senior Vice President - Enterprise Services, Chief Information Officer | |
| Joseph C. Caldarella | Senior Vice President, Corporate Controller | |
| Ann Powell Judge | Senior Vice President - Human Resources | |
| John E. Elicker | Senior Vice President - Public Affairs and Investor Relations |